title: SCIO-469 Scios Inc.
abstract: SCIO-469 is a small-molecule p38 mitogen-activated protein (MAP) kinase inhibitor under development by Scios Inc as a potential oral therapy for inflammatory disorders. By July 2004, SCIO-469 was in phase lib clinical trials for rheumatoid arthritis.
authors.affiliation: University of Ioannina Medical School, Department of Internal Medicine, Division of Rheumatology, Ioannina 45110, Greece. snnikas@yahoo.com
authors.forename: Spyros N
authors.initials: SN
authors.lastname: Nikas
authors.forename: Alexandros A
authors.initials: AA
authors.lastname: Drosos
mesh_terms: D000818:Animals; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004791:Enzyme Inhibitors / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D013329:Structure-Activity Relationship; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors*
chemical_list: D004791:Enzyme Inhibitors; D007211:Indoles; C499748:SCIO-469; D048051:p38 Mitogen-Activated Protein Kinases